Neurocrine Biosciences
NBIX
#1646
Rank
NZ$22.29 B
Marketcap
NZ$222.18
Share price
1.23%
Change (1 day)
8.78%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Revenue for Neurocrine Biosciences (NBIX)

Revenue in 2024: NZ$4.17 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current revenue (TTM ) is NZ$4.50 Billion. In 2024 the company made a revenue of NZ$4.17 Billion an increase over the revenue in the year 2023 that were of NZ$2.98 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Neurocrine Biosciences from 1996 to 2024

Annual revenue

Year Revenue Change
2024NZ$4.17 B39.95%
2023NZ$2.98 B27.26%
2022NZ$2.34 B41.3%
2021NZ$1.65 B14.48%
2020NZ$1.44 B23.89%
2019NZ$1.17 B73.93%
2018NZ$0.67 B195.6%
2017NZ$0.22 B950.94%
2016NZ$21.65 M-25.03%
2015NZ$28.88 M
2014N/A-100%
2013NZ$3.55 M-94.5%
2012NZ$64.59 M-34.88%
2011NZ$99.18 M128.42%
2010NZ$43.42 M968.06%
2009NZ$4.06 M-40.64%
2008NZ$6.84 M328.66%
2007NZ$1.59 M-97.13%
2006NZ$55.69 M-69.28%
2005NZ$0.18 B51.85%
2004NZ$0.11 B-44.21%
2003NZ$0.21 B520.51%
2002NZ$34.47 M-65.28%
2001NZ$99.31 M201.71%
2000NZ$32.91 M2.34%
1999NZ$32.16 M5.95%
1998NZ$30.36 M-32.5%
1997NZ$44.97 M65.5%
1996NZ$27.17 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Pfizer
PFE
NZ$105.48 B 2,240.40%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$100.20 B 2,123.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$99.82 B 2,114.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$1.18 B-73.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ$0.13 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$1.38 B-69.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ$14.86 M-99.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$3.94 B-12.41%๐Ÿ‡ฌ๐Ÿ‡ง UK